# Efficacy and Safety of SPH3127 Tablets on Treating the Diabetic Kidney Disease

> **NCT05593575** · PHASE2 · COMPLETED · sponsor: **Shanghai Pharmaceuticals Holding Co., Ltd** · enrollment: 305 (actual)

## Conditions studied

- Diabetic Kidney Disease

## Interventions

- **DRUG:** SPH3127+SPH3127matching placebo+valsartan matching placebo
- **DRUG:** SPH3127+SPH3127matching placebo+valsartan matching placebo
- **DRUG:** SPH3127+valsartan matching placebo
- **DRUG:** SPH3127 matching placebo+valsartan

## Key facts

- **NCT ID:** NCT05593575
- **Lead sponsor:** Shanghai Pharmaceuticals Holding Co., Ltd
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2023-03-22
- **Primary completion:** 2024-12-31
- **Final completion:** 2024-12-31
- **Target enrollment:** 305 (ACTUAL)
- **Last updated:** 2025-02-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05593575

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05593575, "Efficacy and Safety of SPH3127 Tablets on Treating the Diabetic Kidney Disease". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT05593575. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*